Display options
Cite
Alboraie MA, Afifi ME, Elghamry FG, et al. Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study. Hepat Mon. 2013;13(6):e10810doi: 10.5812/hepatmon.10810.
Alboraie, M. A., Afifi, M. E., Elghamry, F. G., Shalaby, H. A., Elshennawy, G. E., Abdelaziz, A. A., Shaheen, M. U., & Abo El-Seoud, A. R. (2013). Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study. Hepatitis monthly, 13(6), e10810. https://doi.org/10.5812/hepatmon.10810
Alboraie, Mohamed A, et al. "Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study." Hepatitis monthly vol. 13,6 (2013): e10810. doi: https://doi.org/10.5812/hepatmon.10810
Alboraie MA, Afifi ME, Elghamry FG, Shalaby HA, Elshennawy GE, Abdelaziz AA, Shaheen MU, Abo El-Seoud AR. Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study. Hepat Mon. 2013 Jun 16;13(6):e10810. doi: 10.5812/hepatmon.10810. eCollection 2013. PMID: 24046790; PMCID: PMC3773216.
Copy Download .nbib Format: NLM
Share it on

Hepat Mon. 2013 Jun 16;13(6):e10810. doi: 10.5812/hepatmon.10810. eCollection 2013.

Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study.

Hepatitis monthly

Mohamed A Alboraie, Mahmoud E Afifi, Fathy G Elghamry, Helmy A Shalaby, Gamal E Elshennawy, Ahmed A Abdelaziz, Mohamed U Shaheen, Amany R Abo El-Seoud

Affiliations

  1. Department of Internal Medicine, Al-Azhar University, Cairo, Egypt.

PMID: 24046790 PMCID: PMC3773216 DOI: 10.5812/hepatmon.10810

Abstract

BACKGROUND: Non-invasive methods for assessment of hepatic fibrosis are increasingly needed. Recent studies showed that combined elevation of tumor markers CA 19-9 and CA 125 is predictive of severe hepatic fibrosis or cirrhosis with high specificity.

OBJECTIVES: We aimed at developing a new panel of surrogate biomarkers for prediction of the stage of hepatic fibrosis by combining tumor markers with other known biomarkers of hepatic fibrosis.

PATIENTS AND METHODS: A total of 92 patients with different types of chronic liver diseases (chronic hepatitis B, chronic hepatitis C and autoimmune hepatitis), were prospectively enrolled in our cohort. They were subjected to: ALT, AST, GGT, ALP, total bilirubin, INR, total cholesterol, albumin, platelet count, cancer antigen 19-9 (CA 19-9), cancer antigen 125 (CA 125), cancer antigen 15-3 (CA 15-3), haptoglobin, alpha-2-macroglobulin, apolipoprotein A1, abdominal ultrasound, liver biopsy and histological staging of hepatic fibrosis using the METAVIR system.

RESULTS: Combined elevation of CA 19-9 and CA 125 with a summated value > 37 U/mL is predictive of severe hepatic fibrosis or cirrhosis (stage F3-F4 METAVIR) with a probability of 77.6%. Multivariate analysis showed that the most relevant collection of biomarkers for prediction of stage of hepatic fibrosis is: CA 19-9, age, alpha-2- macroglobulin, total bilirubin, platelet count & albumin. We developed a new score, named the "Egy-Score", using a regression equation composed of this panel of biomarkers. Egy-Score could differentiate no or early fibrosis (stage F0-F2 METAVIR) from severe fibrosis or cirrhosis (stage F3-F4 METAVIR) with 83.7% accuracy.

CONCLUSIONS: Non-invasive assessment of hepatic fibrosis could be done using the Egy-Score. Egy-Score could differentiate no or early fibrosis (stage F0-F2 METAVIR) from severe fibrosis or cirrhosis (stage F3 - F4 METAVIR) with 83.7% accuracy.

Keywords: Alpha-Macroglobulins; Biological Markers; CA-19-9 Antigen; Fibrosis; Liver Cirrhosis

References

  1. Lancet. 2008 Mar 8;371(9615):838-51 - PubMed
  2. Virol J. 2011 Feb 08;8:53 - PubMed
  3. Lancet. 1997 Mar 22;349(9055):825-32 - PubMed
  4. Am J Gastroenterol. 2011 Dec;106(12):2121-2 - PubMed
  5. Fibrogenesis Tissue Repair. 2012 Jan 03;5(1):1 - PubMed
  6. Hepatology. 1993 Nov;18(5):1224-31 - PubMed
  7. Hepatol Int. 2011 Jun;5(2):625-34 - PubMed
  8. J Clin Gastroenterol. 2010 Sep;44(8):575-82 - PubMed
  9. Hepatology. 2003 Aug;38(2):518-26 - PubMed
  10. Dig Liver Dis. 2011 Jun;43(6):491-7 - PubMed
  11. J Hepatol. 2010 Dec;53(6):1013-21 - PubMed
  12. Hepatology. 2004 Apr;39(4):1147-71 - PubMed
  13. Clin Chem. 1991 Aug;37(8):1379-83 - PubMed
  14. Dig Dis Sci. 2006 Feb;51(2):338-45 - PubMed
  15. Gastroenterol Hepatol. 2012 Aug-Sep;35(7):488-95 - PubMed
  16. Gastroenterology. 2004 Dec;127(6):1704-13 - PubMed
  17. J Viral Hepat. 2011 Jan;18(1):23-31 - PubMed
  18. J Hepatol. 1995 Jun;22(6):696-9 - PubMed
  19. Clin Mol Hepatol. 2012 Jun;18(2):163-73 - PubMed
  20. J Viral Hepat. 2009 May;16(5):300-14 - PubMed
  21. Dig Dis Sci. 1994 Nov;39(11):2426-32 - PubMed
  22. Gastroenterology. 2008 May;134(6):1670-81 - PubMed
  23. Dig Dis Sci. 2013 Jan;58(1):265-74 - PubMed
  24. J Hepatol. 2013 Jul;59(1):180-2 - PubMed
  25. Eur J Surg Oncol. 2000 Aug;26(5):474-9 - PubMed
  26. Int J Biol Markers. 2000 Jul-Sep;15(3):226-30 - PubMed
  27. Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):40-51 - PubMed
  28. BMC Gastroenterol. 2011 Aug 17;11:91 - PubMed
  29. Hepatology. 2002 Oct;36(4 Pt 1):986-92 - PubMed
  30. Hepatology. 2006 Oct;44(4):925-35 - PubMed
  31. Liver Int. 2013 Aug;33(7):982-90 - PubMed
  32. Gastroenterol Hepatol (N Y). 2008 Aug;4(8):539-41 - PubMed
  33. Expert Rev Mol Diagn. 2004 Sep;4(5):593-7 - PubMed
  34. Arab J Gastroenterol. 2011 Jun;12(2):74-9 - PubMed
  35. Gastroenterology. 2008 Jul;135(1):32-40 - PubMed
  36. Liver Int. 2013 May;33(5):698-705 - PubMed
  37. Clin Chem. 2005 Oct;51(10):1867-73 - PubMed

Publication Types